Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at [email protected].
Articles by Eric Palmer
While remediation costs continued to drag on the financials for Impax Laboratories last year to the tune of nearly $24 million, the drugmaker still saw some improvements in its financials for 2014 and finally bagged approval of its treatment for Parkinson's disease early this year.
Two Indian vaccinemakers are ramping up production of their swine flu vaccines, to replace stocks that were destroyed recently after they expired.
The FDA has decided that not only were the operations of New Jersey-based Med Prep Consulting unsterile, they were illegal.
FDA inspectors returned to a Wockhardt plant in Waluj that it banned in 2013 and weren't impressed by what they found during the weeklong inspection. New concerns were raised.
The ability of Maine consumers to get cheaper drugs from across the Canadian border has been on-again and off-again. Now it is off again.
Federal authorities hoped to make an example of the owner of a small Connecticut pharma manufacturing operation that they said ignored warnings and had polluted waste water dumped into the sewers.
South Korea's Samsung BioLogics has pledged to be a big deal in biosimilars, but so far its biologics subsidiary has produced mostly operating losses for its parent. In anticipation of turning that around, the company will undertake a significant expansion of the biologics plant in Songdo, Incheon, that it opened in 2013.
Sun Pharmaceutical's revenues have taken a double whammy from quality problems the FDA cited at a plant in India. The drugmaker said they were down, both because of the costs of fixing the plant and because the of supply interruption from that effort.
Companies with the ability and capacity to manufacture sterile injectable drugs are becoming popular targets. The injectables business of Claris Lifesciences is now said to be drawing attention from potential buyers.
Actavis says it needs to concentrate on integrating the manufacturing network it will soon get from Allergan and so decided to sell back to private equity investor TPG a small piece of Aptalis. TPG sold Aptalis to Forest Laboratories a year ago just ahead of Forest's buyout by Actavis.